TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18045737
Drug: Cold saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold saline solution (4 degrees C, 39.2 degrees F)
Study: 18045737
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature saline solution (23 degrees C, 73.4 degrees F)
Study: 15332212
Drug: Furosemide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (25 mg/kg/d intravenously or 35 mg/kg/d orally)
Study: 8491238
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg oral dose) during pregnancy
Study: 3545842
Drug: Urokinase 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase 2000 IU kg‐1 h‐1 for 24 hours + heparin
Study: 3545842
Drug: Urokinase 4400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase 4400 IU kg‐1 h‐1 for 12 hours + heparin
Study: 18030175
Drug: estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol valerate (2 mg daily)
Study: 18030175
Drug: estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol valerate in combination with testosterone undecanoate (40 mg every 2 days)
Study: 23870189
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg and propofol 1-2.5 mg/kg
Study: 23870189
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% and propofol 1-2.5 mg/kg
Study: 16802852
Drug: BIBN 4096
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN 4096 BS (single intravenous 10-minute infusion at different dose levels ranging from 0.25 to 10 mg)
Study: 12966321
Drug: Ethanol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.3 g/kg for men, 0.2 g/kg for women)
Study: 8638838
Drug: Stellate ganglion
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stellate ganglion block with 7 ml 1% mepivacaine (n = 10)
Study: 8638838
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 7 ml saline (n = 5)
Study: 8638838
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection with 7 ml mepivacaine into the left deltoid muscle (n = 5)
Study: 1282218
Drug: Synthetic substance
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic substance P (SP) at doses of 0.5, 1, or 1.5 pmol/kg‐1/min‐1 over 60 min
Study: 1282218
Drug: Synthetic substance
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic substance P (SP) at 1.5 pmol/kg‐1/min‐1 after pretreatment with sodium valproate (200 mg 16, 8 and 1 h before the SP test)
Study: 1282218
Drug: Synthetic substance
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic substance P (SP) at the lowest dose (0.5 pmol/kg‐1/min‐1)
Study: 28506776
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi or physical therapy exercise (12 weeks, twice per week)
Study: 23936951
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human erythropoietin (rHuEPO) and aggressive intravenous iron therapy
Study: 20825123
Drug: Bilateral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral treatment of equal intensity
Study: 8666002
Drug: 447C88 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 447C88 200 mg single dose
Study: 8666002
Drug: 447C88 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: 447C88 800 mg single dose
Study: 8666002
Drug: 447C88 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 447C88 200 mg twice daily for 10 days
Study: 31995557
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (200mg daily self-administered suppository)
Study: 26151178
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 50,000 IU VTD3, followed by 25,000 IU at Week 4 and Week 8
Study: 26151178
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 100,000 IU VTD3, followed by 50,000 IU at Week 4 and Week 8
Study: 26151178
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 200,000 IU VTD3, followed by 100,000 IU at Week 4 and Week 8
Study: 21453832
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg (TNT trial)
Study: 21453832
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg (TNT trial)
Study: 21453832
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day (IDEAL trial)
Study: 21453832
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day (IDEAL trial)
Study: 21453832
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day (SPARCL trial)
Study: 16705843
Drug: Western routine
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western routine medical treatment (control)
Study: 9266448
Drug: Intra-arterial carboplatin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial carboplatin chemotherapy at a dose escalated to 1400 mg/hemisphere
Study: 9266448
Drug: Intra-arterial carboplatin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial carboplatin chemotherapy
Study: 29497759
Drug: Computer-based writing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based writing treatment
Study: 21496516
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) bibliotherapy, Japanese translation of a self-help book, duration: 2 months reading period followed by a 2-month follow-up.
Study: 17196044
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM)‐style acupuncture with manual stimulation for depression
Study: 10693157
Drug: Ketamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.3 mg/kg i.v.)
Study: 3523664
Drug: Enprofylline (14.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline (14.1 mg/kg/day)
Study: 3523664
Drug: Theophylline (16.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (16.2 mg/kg/day)
Study: 31567764
Drug: Butorphanol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.1 mg (group I)
Study: 31567764
Drug: Butorphanol 1
Normalized name: butorphanol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 1 mg (group II)
Study: 9593078
Drug: Fluvastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin, 40 mg once daily
Study: 9593078
Drug: Pravastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin, 40 mg once daily
Study: 7640154
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of 1.0 mg clonazepam
Study: 7640154
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of 1.0 mg clonazepam
Study: 7640154
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 0.5 mg clonazepam
Study: 2663163
Drug: guaimesal (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: guaimesal (500 mg, three times daily for seven days)
Study: 28923239
Drug: PA101 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA101 (40 mg)
Study: 25316328
Drug: Paracetamol with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol with NAC administration
Study: 24090377
Drug: Serum phosphorus
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum phosphorus above 5.5 mg/dL
Study: 19508679
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg rhTSH
Study: 18803554
Drug: 0.005 mg
Normalized name: biotin 0.005 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005 mg rhTSH
Study: 17134956
Drug: Rosuvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin therapy (10mg daily) with a low-fat diet
Study: 11692298
Drug: Intranasal zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal zinc gluconate
Study: 30993861
Drug: ipragliflozin 50
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipragliflozin 50 mg daily
Study: 31078831
Drug: Probiotic supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplements (Winclove's Ecologic® Barrier), consumed daily over eight weeks
Study: 31078831
Drug: Placebo, consumed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, consumed daily over eight weeks
Study: 25052347
Drug: Fecal calprotectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal calprotectin (FC) monitoring after stopping TNFα-blocking therapy
Study: 24059585
Drug: Overall smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall smoking cessation outcomes in L phase
Study: 20236148
Drug: TME with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TME with radiosensitizing chemotherapy
Study: 17377092
Drug: Laser-assisted drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-assisted drug delivery at 2.0 J/cm2
Study: 17377092
Drug: Laser-assisted drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-assisted drug delivery at 3.5 J/cm2
Study: 14742768
Drug: β-blockers as
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers as secondary prevention of MI
Study: 14742768
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose β-blockers with slow titration
Study: 14742768
Drug: β-blockers in
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers in post-MI diabetic patients
Study: 14742768
Drug: Lower oral
Normalized name: melatonin/val/chamomile flower ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower oral starting doses of β-blockers
Study: 14742768
Drug: Cardioselective β-blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioselective β-blockers and albuterol
Study: 14742768
Drug: β-blockers in
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers in patients with peripheral arterial disease
Study: 19413903
Drug: Stent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent treatment for coronary disease
Study: 24411083
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg/d
Study: 3587722
Drug: Thyrotropin Releasing
Normalized name: Thyrotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin Releasing Hormone (TRH)
Study: 30380162
Drug: Anti-hepatitis B
Normalized name: Anti-Hepatitis Be virus IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hepatitis B virus core antibody (anti-HBc)
Study: 29105635
Drug: Unani medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unani medicine Renax
Study: 29105635
Drug: Allopathic medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopathic medicine (Spironolactone + Furosemide)
Study: 23658070
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR treatment
Study: 21185559
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate mouth wash second hourly (Group B)
Study: 21185559
Drug: Chlorhexidine 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine 0.2% aqueous oral rinse and second hourly irrigations with sterile water (Group C)
Study: 21185559
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water oral rinse second hourly (Group A)
Study: 17304660
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg qd
Study: 2244403
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg tid
Study: 11214952
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (depot leuprolide 3.75 mg)
Study: 1336675
Drug: Sumatriptan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (3 mg)
Study: 6348714
Drug: Flurbiprofen 25
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 25 mg
Study: 27588943
Drug: 2-L PEG
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L PEG and Ascorbic Acid (Asc)
Study: 27588943
Drug: 1-L PEG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-L PEG, Ascorbic Acid (Asc) and 20 mg Bisacodyl (Bis)
Study: 23312487
Drug: Isoflavone vaginal
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone vaginal gel 4% (1g/day)
Study: 17112001
Drug: Cisplatin monotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin monotherapy
Study: 10722763
Drug: Intravenous montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous montelukast (7 mg)
Study: 10722763
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast (10 mg)
Study: 8623957
Drug: Desflurane with
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane with ondansetron (4 mg IV)
Study: 1564466
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg daily for 4 weeks
Study: 1564466
Drug: Usual postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual postoperative analgesic treatment (diclofenac sodium twice daily for 5-10 days)
Study: 25962813
Drug: Transforaminal steroid
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal steroid injection
Study: 25962813
Drug: Caudal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal steroid injection
Study: 23828834
Drug: Modified Constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Constraint-induced aphasia therapy (CIAT), 3 hours per day for a total of 30 hours of treatment.
Study: 23828834
Drug: Conventional aphasia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional aphasia therapy, 3 hours per day for a total of 30 hours of treatment.
Study: 22315331
Drug: sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 4 mg kg(‐1)
Study: 22315331
Drug: neostigmine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: neostigmine 50 μg kg(‐1)/glycopyrrolate 10 μg kg(‐1)
Study: 18043345
Drug: Contrast material
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast material with iodine concentration of 370 mg/mL (Group B)
Study: 18043345
Drug: Contrast material
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast material with iodine concentration of 300 mg/mL (Group A)
Study: 3235833
Drug: Diuretics (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (hydrochlorothiazide and triamterene)
Study: 3235833
Drug: Diuretics (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (hydrochlorothiazide and triamterene) + methyldopa
Study: 3235833
Drug: Diuretics (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (hydrochlorothiazide and triamterene) + methyldopa (considering all cardiovascular events)
Study: 2144420
Drug: Triglycerides (1.68/0.72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglycerides (1.68/0.72 g)
Study: 2144420
Drug: Free fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free fatty acids (1.35/1.065 g)
Study: 2144420
Drug: Ethyl esters
Normalized name: SHEA BUTTER ETHYL ESTERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl esters (1.86/1.27 g)
Study: 788738
Drug: Inhaled salmefamol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmefamol, 100 mug and 200 mug
Study: 788738
Drug: Inhaled salbutamol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salbutamol, 200 mug
Study: 30963410
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg/day for 8 weeks)
Study: 25826644
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg (0.04 mL of 25 mg/mL) subconjunctival bevacizumab
Study: 25826644
Drug: 0.04 mL
Normalized name: ethanol 0.04 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mL of balanced salt solution
Study: 15197019
Drug: Care manager
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care manager offered education, problem-solving treatment, or support for antidepressant management
Study: 9224457
Drug: Heparin‐surface modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin‐surface modified PMMA IOLs
Study: 8357782
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of quinapril once daily
Study: 3122717
Drug: Astemizole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (30 mg daily for 1 week)
Study: 30030321
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplement (ONS) intervention
Study: 22811447
Drug: Ten weeks
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten weeks of home-based occupational therapy according to the Dutch guidelines of occupational therapy in Parkinson's disease
Study: 22811447
Drug: No occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: No occupational therapy
Study: 18982536
Drug: Medium-nicotine cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-nicotine cigarettes (0.6 mg nicotine)
Study: 18982536
Drug: Low/zero-nicotine cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low/zero-nicotine cigarettes (0.05 mg nicotine)
Study: 16567056
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) advertising
Study: 16567056
Drug: Non-pharmaceutical cessation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmaceutical cessation services (Quitline) ads
Study: 8084247
Drug: Nalbuphine 10
Normalized name: nalbuphine 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 10 mg endovenously every 4 h for the first 12 h and every 6 h for the next 12 h
Study: 8084247
Drug: Nalbuphine 20
Normalized name: nalbuphine 20 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 20 mg endovenously every 4 h for the first 12 h and every 6 h for the next 12 h
Study: 31342247
Drug: Ureteral access
Normalized name: Bos taurus ureter preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ureteral access sheath (UAS) used for stone treatment (group-1)
Study: 30709839
Drug: 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/day ground flaxseed for 6 weeks
Study: 21720788
Drug: P and
Normalized name: P and S
Approvals — FDA: no, EMA: no, PMDA: no
Description: P and E2 (4 mg/d)
Study: 16805685
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment at 160 mJ/pulse at 10 Hz
Study: 8970278
Drug: 10-week behavioral
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10-week behavioral medicine support group intervention
Study: 1457626
Drug: Melatonin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (8 mg)
Study: 6500760
Drug: Mepindolol 10
Normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepindolol 10 mg at 8 a.m.
Study: 6500760
Drug: Mepindolol 10
Normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepindolol 10 mg at 8 p.m.
Study: 31010875
Drug: Exenatide 2
Normalized name: exenatide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2 mg once-weekly
Study: 30033542
Drug: Doxycycline oral
Normalized name: doxycycline Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline oral capsules 40 mg (DFD-09) under fed conditions
Study: 30033542
Drug: Doxycycline oral
Normalized name: doxycycline Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline oral capsules 40 mg (DFD-09) under fasting conditions
Study: 30033542
Drug: Doxycycline oral
Normalized name: doxycycline Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline oral capsules 40 mg (DFD-09)
Study: 12411221
Drug: Transdermal selegiline
Normalized name: selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal selegiline (20 mg applied once daily by means of a 20-cm² patch)
Study: 10636157
Drug: Transdermal selegiline
Normalized name: selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal selegiline
Study: 10449891
Drug: Valsartan in
Normalized name: Product containing valsartan in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan in combination with ACE inhibitors and other prescribed therapies